FDA Expands Approval for Elucirem™ for Pediatric MRI Use

The U.S. Food and Drug Administration (FDA) has authorized a new application for Guerbet's Elucirem™ (gadopiclenol) injection, extending its use for magnetic resonance imaging (MRI) to pediatric patients, including term neonates. This latest approval broadens the usage of this gadolinium-based contrast agent, known for its high relaxivity, across a younger patient demographic.

Elucirem™ has been noted for its capability to operate effectively at half the gadolinium dose compared to other available contrast agents. Initially approved by the FDA in September 2022, and subsequently by the European Medicines Agency in December 2023, Elucirem™ is available in both vials and prefilled syringes. Its innovative formulation allows healthcare providers to use it for adults as well as pediatric patients to identify lesions with abnormal vascularity within the central nervous system and various bodily regions, such as the head, neck, thorax, abdomen, pelvis, and musculoskeletal system.

The advantage of using Elucirem™ lies in its ability to provide high-quality imaging with reduced gadolinium exposure, an important consideration for pediatric patients who may require multiple MRI scans throughout their lives. "The new indication of Elucirem™ for pediatric patients, including term neonates, reflects our commitment to combining medical innovation and patient experience. Imaging departments will be able to perform contrast-enhanced MR imaging using half the conventional gadolinium dose, which is critical for patients, especially those requiring serial MRI examinations during their lifetime, as it reduces cumulative gadolinium exposure," said Jim Patterson, General Manager North America.

Dr. Azam Eghbal, Medical Director of Pediatric Radiology at Children's Hospital of Orange County, emphasized the significance of Elucirem™ in pediatric care, noting that the agent's higher relaxivity allows for quality imaging with minimal gadolinium, which is particularly beneficial for younger patients.

However, the product comes with critical safety warnings associated with its use. The primary risks include serious adverse reactions related to intrathecal use and nephrogenic systemic fibrosis (NSF). Consequently, Elucirem™ is not approved for intrathecal administration, and caution is advised for patients with impaired renal function, who face heightened risks of NSF.

Healthcare professionals are urged to consider these risks and take preventive measures, such as screening for renal function before administration and minimizing repetitive GBCA imaging studies, especially for populations at risk. For further safety information, the FDA encourages reporting of adverse effects and provides comprehensive prescribing details. For more details, please refer to the prescribing information on the FDA website or Guerbet's official website.